Changing general medical practices in the management of neuropathic pain

被引:0
作者
Poucher, Mathieu [1 ]
Cherrier, Claude [2 ]
Poucher, Anne-Christelle [3 ]
Di Patrizio, Paolo [4 ]
机构
[1] 110 Ave Gen Leclerc, F-54500 Vandoeuvre Les Nancy, France
[2] Serv Med Reg Nord Est, 85 Rue Metz, Nancy, France
[3] Ctr Hosp Univ Nancy, Unite Posturgences Polyvalente, 29 Ave Marechal De Lattre Tassigny, Nancy, France
[4] Univ Lorraine, Fac Med, 9 Ave Foret Haye, Vandoeuvre Les Nancy, France
来源
SANTE PUBLIQUE | 2016年 / 28卷 / 04期
关键词
Neuropathic pain; General medicine; Professional; practices; Focus group; PHARMACOLOGICAL-TREATMENT; EFNS GUIDELINES; DISORDERS;
D O I
10.3917/spub.164.0505
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: The objective of this study was to determine current practices in the Lorraine region in the treatment of neuropathic pain and to assess the challenges faced by general practitioners (GPs). Methods: We conducted a qualitative study by the focus group technique, by constituting a balanced panel of GPs to meet diversification requirements. The number of focusgroups was defined to obtain data saturation. The lead author of this study acted as an observer, while a facilitator was responsible for moderating the debate. Analysis of transcripts was performed in two ways: firstly, several readings of the transcripts to highlight the main ideas emerging from these discussions, and secondly, integration of verbatim transcripts in NVivo 10 software to allow complementary computer analysis. Results: The GPs interviewed reported that they prescribed Clonazepam (Rivotril (R)), Carbamazepine (Tegretol (R)) and Amitriptyline (Laroxyl (R)) less often than ten years ago, and Gabapentin (Neuron tin (R)), Pregabalin (Lyrica (R)), Venlafaxin (Effexor (R)) and Duloxetine (Cymbalta (R)) more often than ten years ago. They reported many difficulties in the daily management of these patients, especially concerning the psychological or psychiatric components associated with this pain, comorbidities, iatro-genic effects, the inefficacy of the available molecules, the difficulties of access to a specialist (including pain centres), acceptance of treatment by patients, limiting requirements (restrictive marketing authorisations, withdrawal of certain products...). Conclusion: The treatment of neuropathic pain raises a number of difficulties for GPs, but changes in prescribing habits reflect a constant adaptation of clinical practices.
引用
收藏
页码:505 / 516
页数:12
相关论文
共 29 条
[1]  
Agence nationale de securite du medicament et des produits de sante (ANSM), 2011, SPEC BAS DEXT RETR P
[2]  
Agence nationale de securite du medicament et des produits de sante (ANSM), 2011, MOD COND PRESCR DEL
[3]  
Agence nationale de securite du medicament et des produits de sante (ANSM), 2016, PREG GEL 100 MG
[4]  
Agence nationale de securite du medicament et des produits de sante (ANSM), 2016, RIV SOL BUV
[5]  
Agence nationale de securite du medicament et des produits de sante (ANSM), 2016, RIV CPR 2 MG
[6]  
Agence nationale de securite du medicament et des produits de sante (ANSM), 2016, GAB GEL 400 MG
[7]  
Agence nationale de securite du medicament et des produits de sante (ANSM), 2016, QUT
[8]  
ANSM, 2011, RIV CLON MOD COND PR
[9]   EFNS guidelines on pharmacological treatment of neuropathic pain [J].
Attal, N. ;
Cruccu, G. ;
Haanpaa, M. ;
Hansson, P. ;
Jensen, T. S. ;
Nurmikko, T. ;
Sampaio, C. ;
Sindrup, S. ;
Wiffen, P. .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (11) :1153-1169
[10]   EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision [J].
Attal, N. ;
Cruccu, G. ;
Baron, R. ;
Haanpaa, M. ;
Hansson, P. ;
Jensen, T. S. ;
Nurmikko, T. .
EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (09) :1113-E88